- Aktuelle Seite:
-
Home
- Substitution und Schwangerschaft
Association of Maternal Use of Benzodiazepines and Z-Hypnotics During Pregnancy With Motor and Communication Skills and Attention-Deficit/Hyperactivity Disorder Symptoms in Preschoolers.
Lupattelli A, Chambers CD, Bandoli G, Handal M, Skurtveit S, Nordeng H.
JAMA Netw Open. 2019 Apr 5;2(4):e191435. doi: 10.1001/jamanetworkopen.2019.1435. Erratum in: JAMA Netw Open. 2019 May 3;2(5):e194291.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6450329/
Association of prenatal exposure to benzodiazepines and child internalizing problems: A sibling-controlled cohort study.
Brandlistuen RE, Ystrom E, Hernandez-Diaz S, Skurtveit S, Selmer R, Handal M, et al. (2017)
PLoS ONE 12(7): e0181042. doi.org/10.1371/journal.pone.0181042
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0181042
Opioids Affect the Fetal Brain: Reframing the Detoxification Debate.
Caritis SN, Panigrahy A.
Am J Obstet Gynecol. 2019 Jul 16. pii: S0002-9378(19)30906-8. doi: 10.1016/j.ajog.2019.07.022.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31323217
Treating women with opioid use disorder during pregnancy in Appalachia: Initial neonatal outcomes following buprenorphine + naloxone exposure.
Nguyen L, Lander LR, O'Grady KE, Marshalek PJ, Schmidt A, Kelly AK, Jones HE.
Am J Addict. 2018 Mar;27(2):92-96. doi: 10.1111/ajad.12687.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929133/
Maternal buprenorphine treatment during pregnancy and maternal physiology.
Jansson LM, Velez ML, McConnell K, Milio L, Spencer N, Jones H, DiPietro JA.
Drug Alcohol Depend. 2019 May 31;201:38-44. doi: 10.1016/j.drugalcdep.2019.03.018.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/31176949
Impact of prenatal exposure to benzodiazepines and z-hypnotics on behavioral problems at 5 years of age: A study from the Norwegian Mother and Child Cohort Study.
Sundbakk LM, Wood M, Gran JM, Nordeng H (2019)
PLoS ONE 14(6): e0217830. doi.org/10.1371/journal.pone.0217830
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0217830
Substance Use In Pregnancy.
Prince MK, Ayers D.
StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 May 18.
https://www.ncbi.nlm.nih.gov/books/NBK542330/
Medications to Treat Opioid Use During Pregnancy – An info sheet for providers
This information sheet, for practitioners, explains the importance of concurrent treatment of OUD with prenatal/postpartum care and the importance of providing the materials to clients. (SAMSHA, USA, April 2019)
https://store.samhsa.gov/system/files/pre_pregnancy_info_sheet_042219_508_0.pdf
Pregnancy Planning for Women Treated for Opioid Use Disorder
This fact sheet is for women who are pregnant or of childbearing age with an opioid use disorder. (SAMHSA, USA, April 2019)
https://store.samhsa.gov/system/files/pre_pregnancy_factsheet_041919_508.pdf
Implications of perinatal buprenorphine exposure on infant head circumference at birth.
O'Connor A, O'Brien L, Watson L.
J Matern Fetal Neonatal Med. 2019 Mar 25:1-81. doi: 10.1080/14767058.2019.1599352.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30905231
Cannabis in der Schwangerschaft könnte Psychoserisiko der Kinder erhöhen
St. Louis/Missouri – Kinder, deren Mütter einen Cannabiskonsum in der Schwangerschaft angegeben hatten, wiesen in einer prospektiven Kohortenstudie in JAMA Psychiatry(2019; doi: 10.1001/jamapsychiatry.2019.0076) im Alter von etwa 10 Jahren eine erhöhte Neigung zu psychotischen Symptomen auf. (aerzteblatt.de, 28.03.2019)
Schon eine Zigarette am Tag in der Schwangerschaft verdoppelt das Risiko auf einen Krippentod
Seattle – Rauchen während der Schwangerschaft könnte eine wichtige Ursache für den Krippentod (SIDS) sein. In einer US-Studie in Pediatrics(2019; doi: 10.1542/peds.2018-3325) war bereits für eine tägliche Zigarette ein erhöhtes Risiko nachweisbar, das dosisabhängig anstieg. (aerzteblatt.de, 13.03.2019)
Maternal Smoking Before and During Pregnancy and the Risk of Sudden Unexpected Infant Death
Tatiana M. Anderson, Juan M. Lavista Ferres, Shirley You Ren, Rachel Y. Moon, Richard D. Goldstein, Jan-Marino Ramirez, Edwin A. Mitchell
Pediatrics Mar 2019, e20183325; DOI: 10.1542/peds.2018-3325
https://pediatrics.aappublications.org/content/early/2019/03/07/peds.2018-3325
Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy.
Committee on Obstetric Practice.
Obstet Gynecol. 2017 Aug;130(2):e81-e94. doi: 10.1097/AOG.0000000000002235.
Supporting breastfeeding for infants born to opioid dependent mothers June 18, 2018.
Groer M; Breastfeeding Expert Panel,, Maguire D; Breastfeeding Expert Panel,, Taylor K.
Nurs Outlook. 2018 Sep;66(5):496-498. doi: 10.1016/j.outlook.2018.07.003.
https://www.nursingoutlook.org/article/S0029-6554(18)30394-4/fulltext
USA. Opioid Use Disorders and Medication-Assisted Treatment in Pregnancy
The rate of opioid misuse and dependence is escalating in many communities, including amongst pregnant and parenting women. In addition, substance use treatment systems are reporting increases in the number of individuals seeking treatment for opioid use disorders. Child welfare systems are reporting increases in caseloads, primarily among infants and young children coming into care and hospitals are reporting increases of infants born with neonatal abstinence syndrome. A coordinated, multi-systemic approach that is grounded in early identification and intervention can assist child welfare and treatment systems in conducting both a comprehensive assessment and ensuring access to the range of services needed by families. Collaborative planning and implementation of services are yielding promising results in communities across the country. (SAMHSA - Substance Abuse and Mental Health Services Administration, USA, Stand Februar 2019)
[Increasing Consumption of Crystal Meth in Saxony and its Risks for Mother and Child - Experiences at a Level I Perinatal Center from a Pediatric Viewpoint].
Dinger J, Näther N, Wimberger P, Zimmermann US, Schmitt J, Reichert J, Rüdiger M.
Z Geburtshilfe Neonatol. 2017 Apr;221(2):73-80. doi: 10.1055/s-0043-102953. Epub 2017 May 23. German.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/28561211
WFSBP * and IAWMH ** Guidelines for the treatment of alcohol use disorders in pregnant women.
Thibaut F, Chagraoui A, Buckley L, Gressier F, Labad J, Lamy S, Potenza MN, Rondon M, Riecher-Rossler A, Soyka M, Yonkers K.
World J Biol Psychiatry. 2019 Jan 11:1-34. doi: 10.1080/15622975.2018.1510185.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30632868
Medical Specialty of Buprenorphine Prescribers for Pregnant Women with Opioid Use Disorder.
Hollander MAG, Jarlenski MP, Donohue JM, Cole ES, Kelley D, Krans EE.
Am J Obstet Gynecol. 2019 Jan 28. pii: S0002-9378(19)30256-X. doi: 10.1016/j.ajog.2019.01.226.
https://www.ajog.org/article/S0002-9378(19)30256-X/pdf
Benzodiazepine withdrawal in pregnant women with opioid use disorders: An observational study of current clinical practices at a tertiary obstetrical hospital.
Gopalan P, Moses-Kolko E, Valpey R, Shenai N, Smith E.
Gen Hosp Psychiatry. 2018 Dec 11;57:29-33. doi: 10.1016/j.genhosppsych.2018.12.005.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30669023
Substanzgebrauch in der Schwangerschaft: Willkommen zur CaSCH-T1 Befragung
Die Forschungsgruppe für Cannabinoide der Ludwig-Maximilians-Universität führt eine vom Bundesministerium für Gesundheit geförderte Studie zum Thema „Substanzgebrauch während der Schwangerschaft“ durch. Der Hintergrund dieser Studie ist zu ermitteln, ob und welchen Substanzgebrauch es während der Schwangerschaft in Deutschland gibt, welche Erfahrungen die Frauen und das medizinische Fachpersonal dazu berichten und ob Auswirkungen des Gebrauchs auf Mutter und Kind zu beobachten sind. Dazu führen wir eine anonymeBefragung von schwangeren Frauen und Müttern sowie Ärztinnen und Ärzten, Hebammen und anderem Fachpersonal durch. Die Beantwortung der Fragen wird ungefähr 10 Minuten dauern.
Ihre Teilnahme wird entscheidend dazu beitragen, einen ersten Eindruck zur Häufigkeit und den Effekten des Substanzgebrauchs während der Schwangerschaft zu erhalten. (LMU – Ludwig Maximilian Universität, Klinikum der Universität München, 2018)
https://www.umfragen-am-klinikum.de/index.php/622226
Risk of preterm and early term birth by maternal drug use.
Baer RJ, Chambers CD, Ryckman KK, Oltman SP, Rand L, Jelliffe-Pawlowski LL.
J Perinatol. 2018 Dec 20. doi: 10.1038/s41372-018-0299-0.
Abstract
https://www.ncbi.nlm.nih.gov/pubmed/30573752
USA. Drug Use During Pregnancy Not Child Abuse -Pennsylvania Top Court
(Reuters) - A divided Pennsylvania Supreme Court ruled on Friday that mothers who use illegal drugs during their pregnancies are not committing child abuse against their newly-born children. (Medscape, 31.12.2018)
https://www.medscape.com/viewarticle/907076
Frequency and associated risk factors of non-fatal overdose reported by pregnant women with opioid use disorder.
Bagley SM, Cabral H, Saia K, Brown A, Lloyd-Travaglini C, Walley AY, Rose-Jacobs R.
Addict Sci Clin Pract. 2018 Dec 14;13(1):26. doi: 10.1186/s13722-018-0126-0.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295054/
USA. Slandering the Unborn - How bad science and a moral panic, fueled in part by the news media, demonized mothers and defamed a generation.
Legislative intrusion into the womb has a long history in the United States, and nowhere is this paternalism more forceful than when illegal drugs are part of the equation. If the country’s war on drugs functions as a system of social control, that control is doubly exercised when a fetus is involved. (New York Times, 28.12.2018)
https://www.nytimes.com/interactive/2018/12/28/opinion/crack-babies-racism.html
Childhood neurodevelopment after prescription of maintenance methadone for opioid dependency in pregnancy: a systematic review and meta-analysis.
Monnelly VJ, Hamilton R, Chappell FM, Mactier H, Boardman JP.
Dev Med Child Neurol. 2018 Dec 3. doi: 10.1111/dmcn.14117.
https://onlinelibrary.wiley.com/doi/full/10.1111/dmcn.14117
A retrospective analysis of treatment and retention outcomes of pregnant and/or parenting women with opioid use disorder.
Lopian KM, Chebolu E, Kulak JA, Kahn LS, Blondell RD.
J Subst Abuse Treat. 2019 Feb;97:1-6. doi: 10.1016/j.jsat.2018.11.002.
Abstract
https://www.journalofsubstanceabusetreatment.com/article/S0740-5472(18)30355-6/fulltext
Charité: Suchterkrankungen in der Schwangerschaft (Themenseite)
Die Klinik für Geburtsmedizin hat seit Jahren ein bereits in der Schwangerschaft beginnendes Betreuungskonzept für Suchtmittel konsumierende Schwangere etabliert.
Uns ist es wichtig Sie nicht nur zu den sogennanten illegalen Drogen wie Heroin, Kokain, Crystal Meth und Cannabis, sondern insbesondere auch zu Alkohol und Nikotin zu beraten und Ihnen Hilfe anzubieten. (Charité, Berlin, 2018)
https://geburtsmedizin.charite.de/leistungen/suchterkrankungen/
USA. Caught in Chaos—When Pregnant Women With OUD Are Incarcerated; How OTPs Can Help
This is the story of a young woman with a 15-year history of severe opioid use disorder (OUD), intermittent hospitalization, and incarceration, who becomes pregnant. She has a history of trauma and mental health issues, and few social supports. Her story is the subject of a case report recently published in the Journal of Addiction Medicine. (ATForum, USA, 17.12.2018)
http://atforum.com/2018/12/chaos-pregnant-women-oud-incarcerated/
USA. MATER Center Director, on the Importance of Dr. Finnegan’s Work—Which Continues—and the Need to Treat Mothers for Trauma
Loretta Finnegan, MD, a champion of medication-assisted treatment with methadone, developed her scoring system for newborns more than 40 years ago. The Finnegan Neonatal Abstinence Scoring System (FNASS) assigns a numerical score to 21 clinical signs, and babies are treated accordingly. Developing the test was an important step in making sure that these babies were treated with morphine, if necessary, to manage the symptoms of withdrawal.
But the work of Dr. Finnegan goes far beyond the Finnegan score. When she first started an opioid treatment program (OTP) at Thomas Jefferson University in Philadelphia, 44 years ago, Dr. Finnegan opened a landmark program for pregnant women addicted to opioids. Since then, the program, called Maternal Addiction Treatment Education & Research (MATER), has included intensive outpatient treatment as well as residential treatment.
Diane Abatemarco, PhD, MSW, director of MATER and associate professor of OB/GYN and Pediatrics at the Sidney Kimmel Medical College at Jefferson, talked with AT Forum about the scope and importance of Dr. Finnegan’s work. (ATForum, USA, 17.12.2019)
http://atforum.com/2018/12/mater-center-director-finnegans-work/
Seite 1 von 4